US Investors Back Australian Innovation with US$12m – Using AI to Detect and Prevent Disease through Eye Scans
Melbourne, Australia, 15 MAY 2023 – New York-based healthtech company creation platform Ascertain is investing US$12 (A$18) million in Eyetelligence, a Melbourne-based healthtech company which uses advanced artificial intelligence (AI) technology and retinal imaging to screen for eye and systemic diseases.
Australian First: TGA Approved AI Platform for Optometry
Mivision editor, Melanie Kell, interviews Professor Harry Weisinger on the announcement of the new Eyetelligence clinical decision-support software.
Professor He Awarded Major MRFF Grant
Eyetelligence’s CMO, Professor He, was awarded a $5M grant by MRFF to lead development of an integrated AI eye screening system for use in primary care settings. Eyetelligence named as exclusive technical and commercial partner.
Expanding Horizons In Pursuit of Disease Detection
Mivision editor, Melanie Kell, interviews Professor Ming He, our Chief Medical Officer on why he is so passionate about eye health, and what drives him to pursue excellence in his field and on the study of AI.
Research & Development
Our AI models have been years in development with a dedicated team. The AI has been trained using 200,000+ retinal images, labelled by a panel of subspecialist ophthalmologists. Our papers on the AI models have been published and peer reviewed.
Get in touch with our team today. We’re here to help you and ready to answer your questions and enquiries.